News
ABBV
175.58
+2.37%
4.06
If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy
Seeking Alpha · 13h ago
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
The Motley Fool · 16h ago
Validea Detailed Fundamental Analysis - ABBV
NASDAQ · 1d ago
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
Barchart · 1d ago
Impax Small Cap Fund Q3 2024 Commentary
Seeking Alpha · 2d ago
AbbVie Says Canadian Headache Society Backs Atogepant, OnabotulinumtoxinA
NASDAQ · 2d ago
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of Patients, With Benefits Outweighing Potential Risks
Benzinga · 2d ago
Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65
Seeking Alpha · 2d ago
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
The Motley Fool · 2d ago
Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla
NASDAQ · 3d ago
PBMs took payments from manufacturers to allow free flow of opioids, NYT reports
TipRanks · 3d ago
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
NASDAQ · 3d ago
My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys
Seeking Alpha · 3d ago
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
NASDAQ · 3d ago
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
NASDAQ · 3d ago
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Barchart · 3d ago
Noteworthy Tuesday Option Activity: ABBV, SLQT, TTD
NASDAQ · 4d ago
Barclays fact-checked Trump comments on pharmacy benefit managers
TipRanks · 4d ago
AbbVie Is Maintained at Overweight by Piper Sandler
Dow Jones · 4d ago
Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $220
Benzinga · 4d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It researches and develops, manufactures, commercializes and sells medicines and therapies. Its product portfolio includes immunology, oncology, aesthetics, neuroscience, eye care and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Diffuse large B-cell lymphoma. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers and others. Its NX-13 for the treatment of ulcerative colitis and Crohn's disease. Its CEL383 for the treatment of inflammatory bowel disease. Its ALIA-1758 for the treatment of patients with Alzheimer's disease.